Everything below concerns SR9009. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-11. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common supplier description |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water |
| Typical storage | −20 °C, desiccated, dark | For research samples |
| Analytical method | LC-MS/MS | Used for detection and quantification |
| Regulatory status | Prohibited in sport | WADA metabolic modulator class |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Selective serotonin reuptake inhibitors, or serotonin-specific re-uptake inhibitor (SSRIs), are a class of chemical compounds that have application as antidepressants and in the treatment of depression and other psychiatric disorders. SSRIs are therapeutically useful in the treatment of panic disorder (PD), posttraumatic stress disorder (PTSD), social anxiety disorder (also known as social phobia), obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), and anorexia. There is also clinical evidence of the value of SSRIs in the treatment of the symptoms of schizophrenia and their ability to prevent cardiovascular diseases. SSRIs primarily inhibit serotonin transporter (SERT) in the brain and have negligible effects on dopamine transporter (DAT) and norepinephrine transporter (NET). Inhibiting the binding of the neurotransmitter serotonin (5-HT) to SERT results in increased 5-HT concentration in the synaptic cleft leading to increased binding of 5-HT to postsynaptic receptors. This was once thought to be the mechanism that resulted in improvement of depression symptoms, however more recent systematic review of the academic literature has established that there is no correlation between 5-HT concentration or activity in the brain and depressive symptoms. SSRIs have dominated the market for antidepressants and are recommended by the National Institute for Health and Clinical Excellence (NICE) as a first-line treatment of depression, because they tend to have fewer adverse effects than other type of antidepressants with the same effectiveness.
=== IRTA === The International Refrigerated Transportation Association (IRTA) was established in 1994 to meet a growing demand in the transportation industry for chilled and frozen food products. IRTA was led by a core group of international companies, including companies which specialize in transportation categories across the cold chain. IRTA members were companies primarily involved in ports, trucking, warehousing, logistics, marine shipping, railroads, and airplane transportation, or any combination of these industries.
Canning is a way of processing food to extend its shelf life. The idea is to make food available and edible long after the processing time. A 1997 study found that canned fruits and vegetables are as rich with dietary fiber and vitamins as the same corresponding fresh or frozen foods, and in some cases the canned products are richer than their fresh or frozen counterparts. The heating process during canning appears to make dietary fiber more soluble, and therefore more readily fermented in the colon into gases and physiologically active byproducts. Canned tomatoes have a higher available lycopene content. Consequently, canned meat and vegetables are often among the list of food items that are stocked during emergencies.
Sources: en.wikipedia.org
KGOP01 (H-Dmt-d-Arg-Aba-β-Ala-NH2) is a synthetic peptide derivative which acts as a potent agonist of opioid receptors and has analgesic effects. It was originally derived from modification of dermorphin, a naturally occurring opioid peptide secreted by some species of South American frogs. While numerous opioid peptides are known and widely used in scientific research, such as DAMGO and DADLE, these are rapidly metabolised in the body and fail to cross the blood-brain barrier, and so do not produce centrally mediated analgesic effects. KGOP01 on the other hand contains several unnatural amino acids and is both metabolically stable and able to enter the brain, resulting in potent analgesic effects in animal studies. Because it is a peptide, it can be readily hybridised with other peptide ligands and so has been widely used to produce hybrid compounds combining opioid activity with activity at receptors for neuropeptides such as nociceptin, neurokinin, neurotensin and neuropeptide FF, which may lead to the development of improved opioid analgesics with reduced side effects.
A collaboration between Fred McLafferty and Roland Gohlke and William C. Wiley and Daniel B. Harrington of Bendix Aviation in the 1950s led to the combination of gas chromatography and mass spectrometry, and the development of Gas chromatography–mass spectrometry instrumentation. Beginning in the 1960s, Bendix produced scientific instruments such as the Bendix MA-2 Time-of-Flight Mass Spectrometer.
Liquid metal molybdenum-containing targets have been proposed that would aid in streamlined processing, ensuring better production yields. A particular problem associated with the continued reuse of recycled, enriched 100Mo targets is unavoidable transmutation of the target as other Mo isotopes are generated during irradiation and cannot be easily removed post-processing.
=== "One Strike and You're Out" policy" === Scholars have argued that Clinton's policies came in an attempt to swing back the tide of white voters who had left the party two decades earlier to support Reagan. The Clinton administration articulated that the policies were an attempt to be fiscally conservative and to slash the federal budget deficit. During the administration, the federal budget saw a reduction in public housing funding by $17 billion. The federal corrections programs received a $19 billion, which a 61 percent decrease in public housing funding and a 171 percent increase in federal prison budgeting. Scholars argue that the construction of federal prisons replaced the major public housing programs for the urban poor. Clinton's "One Strike and You're Out" policy stated, "From now on, the rule for residents who commit crime and peddle drugs should be one strike and you're out." Any tenant of public housing convicted of any drug-related offence would no longer have access to public housing.
Sources: en.wikipedia.org
Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. It is given by mouth. Common side effects include bone marrow suppression. Other serious side effects include an increased long term risk of further cancer, infertility, and allergic reactions. Use during pregnancy often results in harm to the baby. Chlorambucil is in the alkylating agent family of medications. It works by blocking the formation of DNA and RNA. Chlorambucil was approved for medical use in the United States in 1957. It is on the World Health Organization's List of Essential Medicines. It was originally made from nitrogen mustard.
=== Confidence === The formation of the Bellido cabinet was instantly met with opposition, and in the opposition-controlled Congress, there was the risk that Congress would not give trust to the cabinet. Some believed that the Bellido cabinet was a "shock cabinet" with the attempt of baiting Congress into denying confidence twice so that it could be shut down, as it was during the 2019–2020 Peruvian constitutional crisis. A congressman from Free Peru claimed that Congress was attempting to impeach the President, and warned that if trust is denied twice then Congress will be dissolved. While Vice President Dina Boluarte rejected the possibility of dissolving Congress, it nonetheless remained a contentious issue. During the impeachment attempt against former Labor Minister Iber Maraví over his alleged link to Shining Path, then Prime Minister Guido Bellido threatened to use trust to defend Maraví. As a result, Congress passed a law which would reinterpret the question of confidence and would restrict its applicability. Justice Minister Aníbal Torres claimed that this reinterpretation would challenge the constitutional balance of power, and stated that he would challenge the reinterpretation bill via the Constitutional Court. It's worth noting that the makeup of the Constitutional Court is set to be replaced by Congress, as its current term expired in 2019 (the court remained in operation as Congress couldn't agree on successors).
JEOL, Ltd. (日本電子, Nihon Denshi Kabushiki-kaisha; Nihon meaning Japan and Denshi meaning electron) is a major developer and manufacturer of electron microscopes and other scientific instruments, industrial equipment and medical equipment. Its headquarters are in Tokyo, Japan, with 25 domestic and foreign subsidiaries and associated companies as of 2014. It is listed in the top ten businesses worldwide for analytical laboratory instrument manufacturing. It has been included in the Activest Lux Nanotech Mutual Fund and the WestLB Nanotech Fund.
Cold fusion researchers (McKubre since 1994, ENEA in 2011) have speculated that a cell that is loaded with a deuterium/palladium ratio lower than 100% (or 1:1) will not produce excess heat. Since most of the negative replications from 1989 to 1990 did not report their ratios, this has been proposed as an explanation for failed reproducibility. This loading ratio is hard to obtain, and some batches of palladium never reach it because the pressure causes cracks in the palladium, allowing the deuterium to escape. Fleischmann and Pons never disclosed the deuterium/palladium ratio achieved in their cells; as of 2002 there were no longer any batches of the palladium used by Fleischmann and Pons because the supplier changed the manufacturing process, and researchers still had problems finding batches of palladium that achieved heat production reliably.
Also in 2008, DiCaprio starred in Body of Lies, a spy film based on the novel of the same name. He played one of three agents battling a terrorist organization in the Middle East. Considering the film to be a throwback to political features of the 1970s like The Parallax View (1974) and Three Days of the Condor (1975), DiCaprio dyed his hair brown and wore brown contacts for the role. The film received mixed reviews from critics, and grossed $118 million against a budget of $67.5 million. Later in 2008, DiCaprio collaborated with Kate Winslet for the drama Revolutionary Road, directed by her then-husband Sam Mendes. As both actors had been reluctant to make romantic films similar to Titanic, it was Winslet who suggested that they both work with her on a film adaptation of the 1961 eponymous novel by Richard Yates. She found that the script, by Justin Haythe, had little in common with the 1997 blockbuster. Playing a couple in a failing marriage in the 1950s, DiCaprio and Winslet spent some time together in preparation, and DiCaprio felt claustrophobic on the small set they used. He saw his character as "unheroic", "slightly cowardly" and someone "willing to be just a product of his environment". Peter Travers liked DiCaprio's pairing with Winslet and his multi-layered portrayal of an overwhelmed character, and Marshall Sella of GQ called it the "most mature and memorable performance of his lifetime". DiCaprio earned his seventh Golden Globes nomination for the film. Revolutionary Road grossed $75.9 million against its budget of $35 million.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.
Detection commonly uses liquid chromatography–tandem mass spectrometry. This method can identify the compound in urine or blood at low concentrations.
Typical guidance is −20 °C, dry, and protected from light. Solutions should be aliquoted and limited freeze–thaw cycles should be used.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.